NASDAQ: APVOAptevo Therapeutics Inc Stock
$0.68-0.06 (-8.11%)
Updated Apr 24, 2024
APVO Price
$0.68
Fair Value Price
N/A
Market Cap
$364.36k
52 Week Low
$0.67
52 Week High
$90.20
P/E
-0.01x
P/B
0.03x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$17.41M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.03
Operating Cash Flow
-$12M
Beta
1.02
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
APVO Overview
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how APVO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APVO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
APVO is good value based on its book value relative to its share price (0.03x), compared to the US Biotechnology industry average (5.86x)
P/B vs Industry Valuation
APVO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more APVO due diligence checks available for Premium users.
Be the first to know about important APVO news, forecast changes, insider trades & much more!
APVO News
Valuation
APVO fair value
Fair Value of APVO stock based on Discounted Cash Flow (DCF)
Price
$0.68
Fair Value
$2.25
Undervalued by
69.84%
APVO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
APVO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.01x
Industry
15.69x
Market
41.27x
APVO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.03x
Industry
5.86x
APVO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
APVO's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.9M
Profit Margin
0%
APVO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$24.8M
Liabilities
$12.6M
Debt to equity
1.03
APVO's short-term assets ($19.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APVO's short-term assets ($19.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APVO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
APVO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.3M
Investing
$0.0
Financing
$3.0M
APVO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
APVO vs Biotech Stocks
Aptevo Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.